fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.
Company profile
Ticker
LAB
Exchange
Website
CEO
Stephen Linthwaite
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FLUIDIGM CORP
SEC CIK
Corporate docs
Subsidiaries
SB Sciences Inc. • Standard BioTools (Shanghai) Instrument Technology Company Limited • Standard BioTools K.K. • Standard BioTools Europe B.V. • Standard BioTools Singapore Pte. Ltd. • SomaLogic, Inc. • Standard BioTools France SARL • Standard BioTools GmbH • Standard BioTools Italy S.r.l. • Standard BioTools UK Limited ...
IRS number
770513190
LAB stock data
Latest filings (excl ownership)
8-K
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
25 Apr 24
8-K
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
18 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
EFFECT
Notice of effectiveness
8 Feb 24
EFFECT
Notice of effectiveness
8 Feb 24
CORRESP
Correspondence with SEC
5 Feb 24
CORRESP
Correspondence with SEC
5 Feb 24
S-3/A
Shelf registration (amended)
2 Feb 24
UPLOAD
Letter from SEC
1 Feb 24
Transcripts
LAB
Earnings call transcript
2023 Q4
28 Feb 24
LAB
Earnings call transcript
2023 Q3
7 Nov 23
LAB
Earnings call transcript
2023 Q2
8 Aug 23
LAB
Earnings call transcript
2023 Q1
9 May 23
LAB
Earnings call transcript
2022 Q4
14 Feb 23
LAB
Earnings call transcript
2022 Q3
9 Nov 22
LAB
Earnings call transcript
2022 Q2
9 Aug 22
LAB
Earnings call transcript
2022 Q1
8 May 22
LAB
Earnings call transcript
2021 Q3
9 Nov 21
LAB
Earnings call transcript
2021 Q3
8 Nov 21
Latest ownership filings
4
Michael Egholm
9 Apr 24
4
Michael Egholm
5 Apr 24
4
Hanjoon Alex Kim
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
20 Mar 24
3
OLE ANDREAS HALVORSEN
20 Mar 24
4
Eli Casdin
20 Mar 24
SC 13D/A
Casdin Capital, LLC
20 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 80.45 mm | 80.45 mm | 80.45 mm | 80.45 mm | 80.45 mm | 80.45 mm |
Cash burn (monthly) | 20.88 mm | (no burn) | 7.06 mm | 6.36 mm | 3.80 mm | 4.03 mm |
Cash used (since last report) | 143.86 mm | n/a | 48.62 mm | 43.82 mm | 26.21 mm | 27.79 mm |
Cash remaining | -63.41 mm | n/a | 31.83 mm | 36.63 mm | 54.24 mm | 52.66 mm |
Runway (months of cash) | -3.0 | n/a | 4.5 | 5.8 | 14.3 | 13.1 |
Institutional ownership, Q3 2023
16.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 73 |
Opened positions | 15 |
Closed positions | 9 |
Increased positions | 16 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 137.18 bn |
Total shares | 48.79 mm |
Total puts | 15.80 k |
Total calls | 10.30 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Caligan Partners | 7.62 mm | $22.10 bn |
Indaba Capital Management | 7.45 mm | $21.59 bn |
Neuberger Berman | 4.54 mm | $13.17 bn |
MS Morgan Stanley | 4.45 mm | $12.91 bn |
Vanguard | 3.97 mm | $11.53 bn |
Primecap Management | 3.08 mm | $8.94 bn |
Balyasny Asset Management | 2.70 mm | $7.82 bn |
Hollow Brook Wealth Management | 1.79 mm | $5.18 bn |
BLK Blackrock | 1.37 mm | $3.96 bn |
North Sound Trading | 1.36 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Michael Egholm | Common Stock | Payment of exercise | Dispose F | No | No | 2.71 | 102,564 | 277.95 k | 531,592 |
5 Apr 24 | Hanjoon Alex Kim | Common Stock | Grant | Acquire A | No | No | 0 | 70,702 | 0.00 | 211,068 |
4 Apr 24 | Hanjoon Alex Kim | Common Stock | Option exercise | Acquire M | No | No | 0 | 70,183 | 0.00 | 140,366 |
4 Apr 24 | Hanjoon Alex Kim | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 70,183 | 0.00 | 140,366 |
18 Mar 24 | Casdin Partners Master Fund | Common Stock | Grant | Acquire A | Yes | No | 2.75 | 13,939,637 | 38.33 mm | 13,939,637 |
18 Mar 24 | Casdin Partners Master Fund | Common Stock | Grant | Acquire A | Yes | No | 2.75 | 32,525,821 | 89.45 mm | 44,023,749 |
18 Mar 24 | Casdin Partners Master Fund | Series B-1 Convertible Preferred Stock Common Stock | Sale back to company | Dispose D | Yes | No | 2.75 | 38,334 | 105.42 k | 0 |
18 Mar 24 | Casdin Partners Master Fund | Series B-1 Convertible Preferred Stock Common Stock | Sale back to company | Dispose D | Yes | No | 2.75 | 89,446 | 245.98 k | 0 |
5 Mar 24 | Casdin Partners Master Fund | Common Stock | Buy | Acquire P | No | No | 2.615 | 1,403 | 3.67 k | 11,497,928 |
4 Mar 24 | Casdin Partners Master Fund | Common Stock | Buy | Acquire P | No | No | 2.57 | 250,000 | 642.50 k | 11,496,525 |
News
Standard BioTools Plans Operational Restructuring; Implements Reduction Of Approximately 10% Of Its Total Workforce
25 Apr 24
TD Cowen Initiates Coverage On Standard BioTools with Buy Rating, Announces Price Target of $3.5
16 Apr 24
Jefferies Initiates Coverage On Standard BioTools with Buy Rating, Announces Price Target of $3.25
4 Apr 24
Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The SomaScan Platform For Translational Medicine Research Through 2026
3 Apr 24
Quantum-Si And 2 Other Penny Stocks Insiders Are Buying
7 Mar 24
Press releases
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
25 Apr 24
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
25 Apr 24
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
8 Apr 24
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
3 Apr 24
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24